中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

52 records (took 0.024 seconds)

    PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF IMMUNE DISORDERS
    1.
    发明公开
    PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF IMMUNE DISORDERS 失效
    药物组合物免疫疾病的治疗

    公开(公告)号：EP0929568A2

    公开(公告)日：1999-07-21

    申请号：EP97939105.0

    申请日：1997-09-10

    Applicant: Prendergast, Patrick Thomas

    Inventor： Prendergast, Patrick Thomas

    IPC: C12N15 ,  A61K38 ,  A61K39 ,  A61P17 ,  A61P25 ,  A61P31 ,  A61P33 ,  A61P37 ,  A61P43 ,  C07K5 ,  C07K7 ,  C07K14 ,  C07K16 ,  C12P21

    CPC classification number: C07K14/005 ,  A61K38/06 ,  A61K38/2026 ,  A61K38/2066 ,  A61K39/00 ,  C07K14/5434 ,  C07K16/1063 ,  C07K16/18 ,  C07K16/244 ,  C07K16/247 ,  C12N2740/15022 ,  C12N2740/16122 ,  Y02A50/412

    Abstract: Herein is described a specific amino acid sequence which exhibits specific Ion (bridge) pair arrays enclosed on at least one side by non polar hydrophobic transmembrane segments, as a mechanism used by many infectious agents and a number of cytokine inhibitory factors, such as Interleukin 10 and Prolactin Inhibitory factor and alfa-fetoprotein, to not only undermine the hosts immune defences but to also allow for the infection of target lymphoid tissue. It has been demonstrated that certain vaccines, when inoculated into a host, produced a range of neutralising antibodies but failed to prevent infection when that host is later challenged with live infectious organism. This present patent illustrates that when such vaccine inoculation is coupled with passive immunisation with mono or polyclonal antibodies to these specific amino acid sequences as specificied herein that the host is then capable of overcoming the infectious challenge. Herein is described the therapeutic use of mono or polyclonal antibodies to these said specific sequences as a treatment for Acquired Immune Deficiency Syndrome (AIDS) and other disease states that persist due to the presence of a cytokine inhibitory factor of viral, fungal, bacterial or host origin such as Chronic Fatigue Syndrome where Interleukin 10 mimic molecules are responsible for a multitude of disease symptoms identified as indicative of Myalgic Encephalitis. Herein is described the therapeutic use of mono or polyclonal antibodies to these specific amino acid sequences as a combination therapy with vaccines and anti-viral agents to prevent side effects from certain immune modulation and anti-viral agents (e.g. DHEA and IL-12) which cause enhanced production of Interleukin 10 or AFP mimic molecules during therapy. Also herein is described the therapeutic use of these specific sequences either isolated from the organism source or produced by direct synthesis or recombinant protein synthesis. These peptides when administered to a patient suffering from an auto-immune disease, such as Multiple Sclerosis (MS), Lupus (systemic Lupus erythematoses) or diabetes or rheumatoid arthritis as limited examples or to transplant organ recipients, will allow the patient's immune state to be shifted to a Th2 antibody dependent immune response and curtail the Th1 (T cell dependent) immune attack which is evident in such immune malfunctions as MS and graft versus host disease. Certain dermatological conditions which are today treated by the use of corticosteroid creams and ointment may also be successfully treated by replacing the corticosteroid with these mimic immunosuppressive AFP/Interleukin 10 sequences outlined in this patent.

    DHEA COMBINATION THERAPY
    2.
    发明公开
    DHEA COMBINATION THERAPY 失效
    DHEA组合疗法

    公开(公告)号：EP0901375A1

    公开(公告)日：1999-03-17

    申请号：EP97917365.0

    申请日：1997-04-17

    Applicant: Prendergast, Patrick Thomas

    Inventor： Prendergast, Patrick Thomas

    IPC: A61K45 ,  A61K31 ,  A61K39 ,  A61P31 ,  A61P33 ,  A61P37

    CPC classification number: A61K45/06

    Abstract: There are provided medicaments, methods of making them, and kits, which include (1) a 17-ketosteroid compound and/or (2) anti-serum either poly- or monoclonal to Interleukin 10, Interleukin 2 or Interleukin 12, or with any compound which can effectively inhibit synthesis or the biological function of Interleukin 10, Interleukin 12 or Interleukin 2, or with an Interleukin 10, Interleukin 12, or Interleukin 2 receptor molecule blocking agent, or with anti-serum, either polyclonal or monoclonal to human alpha-fetoprotein. There are also provided methods of treatment involving such compounds or combinations of compounds, including enhancing Th1 immune protective response when using the 17-ketosteroid compound as an anti-viral, anti-bacterial, anti-mycoplasm or anti-intra cellular parasitic agent, and other treatments for various compounds and combinations as described.

    Use of particular compounds for manufacture of pharmaceutical formulations for metabolic treatments
    3.
    发明公开
    Use of particular compounds for manufacture of pharmaceutical formulations for metabolic treatments 失效
    使用用于治疗代谢的药物制剂中的用途具体的化合物。

    公开(公告)号：EP0468441A1

    公开(公告)日：1992-01-29

    申请号：EP91112320.6

    申请日：1991-07-23

    Applicant: Prendergast, Patrick Thomas

    Inventor： Prendergast, Patrick Thomas

    IPC: A61K39/00 ,  A61K39/12 ,  A61K39/21 ,  A61K37/02 ,  A61K39/395

    CPC classification number: C07K14/005 ,  A61K38/1709 ,  A61K39/00 ,  C07K16/1054 ,  C07K16/1063 ,  C07K16/18 ,  C12N2740/16122 ,  C12N2740/16222

    Abstract: There is provided the use of: 1. Group (A) Compounds - Arachidonic Acid binding peptides for the manufacture of pharmaceutical formulations for use as antigen to stimulate a therapeutic antibody response which can inactivate disease causing agents in the form of viruses, bacteria or mycoplasma; 2. Group (B) Compounds - Antibodies, either mono or polyclonal, produced to compounds of Group (A) for the manufacture of pharmaceutical formulations for administration to a patient (animal or human), particularly where the immune response would not be considered capable of producing enough antibodies to antigens of Group (A); 3. Group (C) Compounds - Unsaturated Fatty Acids, of carbon chain length greater than 18, which have been shown to have a greater affinity for Arachidonic Acid binding peptides than Arachidonic Acid itself, for example, docosahexaenoic acid and eicosapentaenoic acid, for the manufacture of pharmaceutical formulations. These fatty acids can be used as therapeutic agents in place of or in combination with compounds of Group (A) and/or Group (B).

    Abstract translation: 本发明提供的使用：1.组（A）的化合物 - 花生四烯酸结合肽在制备药物配方和灰用作抗原以刺激治疗性抗体应答，其可以在病毒，细菌或支原体的形式灭活致病剂 ; 组2（B）的化合物 - 抗体，无论是单或多克隆的，产生的组（A），用于给药的药物配方和灰中的用途的化合物的患者（动物或人），特别是在免疫应答将不会被认为能够 生产足够的抗体组（A）的抗原; 3.组（C）的化合物 - 不饱和脂肪酸，碳链长度大于18，这已被证明具有用于花生四烯酸结合肽比花生四烯酸本身，例如，十二碳六烯酸和二十碳五烯酸，对于具有更大的亲和力 制造的药物配方和灰。 这些脂肪酸可以用作代替或与组（A）和/或组（B）的化合物组合的治疗剂。

    Use of particular compounds for manufacture of pharmaceutical formulations for treatment against various parasites, mycoplasmas, other indications and other infections
    4.
    发明公开
    Use of particular compounds for manufacture of pharmaceutical formulations for treatment against various parasites, mycoplasmas, other indications and other infections 失效
    使用用于抗多种寄生虫，支原体，其他指示和其他感染治疗的药物制剂中的用途具体的化合物。

    公开(公告)号：EP0462621A2

    公开(公告)日：1991-12-27

    申请号：EP91110263.0

    申请日：1991-06-21

    Applicant: Prendergast, Patrick Thomas

    Inventor： Prendergast, Patrick Thomas

    IPC: A61K31/70

    CPC classification number: A61K31/70 ,  Y02A50/409 ,  Y02A50/492

    Abstract: One or more compounds are used for the manufacture of a pharmaceutical formulation for treatment against one or more kinds of parasites and/or one or more diseases caused by such parasites, against one or more kind of Mycoplasma and/or one or more diseases caused by such Mycoplasmas and/or against one or more of the following indications or infections (a) hairy leukoplakia, (b) oral candidosis, (c) mouth ulcerations-aphthous/herpetic/bacterial, (d) fungal candida, (e) human papilloma virus, (f) molluscum contagiosum, (g) squamous oral carcinoma, (h) Kaposi's sarcoma oral lesions, (i) periodontitis, 0) necrotizing gingivitis, (k) orofacial herpes zoster, and (I) rotaviruses. The present invention furthermore provides specific formulations including such compound(s).

    Abstract translation: 被用于制造药物制剂用于治疗抗寄生虫的一个或更多个种和/或通过寻求寄生虫引起的一种或多种疾病的一种或多种化合物，对一种或多种种类支原体和/或一种或多种疾病所致 求支原体和/或对一种或多种以下指示或感染的（a）中毛状白斑，（b）中口腔念珠菌病，（c）中口溃疡-口疮性/疱疹/细菌，（d）中的真菌念珠菌，（e）中的人类乳头状瘤 病毒，（F）传染性软疣，（G）口腔鳞状细胞癌，（H）卡波济氏肉瘤口腔损伤，（ⅰ）牙周炎，（j）的坏死性牙龈炎，（k）的口面带状疱疹，和（l）轮状病毒。 本发明进一步更具体提供式蒸发散包括检查化合物（S）。

    A shield for electronic apparatus
    5.
    发明公开
    A shield for electronic apparatus 失效
    Abschirmungfürelektronische Apparate。

    公开(公告)号：EP0200513A1

    公开(公告)日：1986-11-05

    申请号：EP86303190.2

    申请日：1986-04-28

    Applicant: Prendergast, Patrick Thomas ,  Prendergast, Mary Josephine ,  Prendergast, Patrick Edward ,  Shanahan-Prendergast, Elizabeth ,  Prendergast, Leo Joseph

    Inventor： Prendergast, Patrick Thomas

    IPC: H05K9/00

    CPC classification number: H05K9/0054

    Abstract: A shield (1) for electronic apparatus (2) such as a visual display unit (2) to prevent or reduce emission of radiated signals, such as radio waves, comprises a base (8) to support the visual display unit (2) and a cover (9) extending over the unit (2) and in secure electrical engagement with the base (8). The base (8) is of sheet metal, and the cover (9) is formed from a single sheet of nickel coated woven polyester textile material stitched together. The cover (9) and base (8) are secured by metallised hooks and loops fasteners (36,37). A transparent electrically conductive screen (44) provides visual access to the visual display unit (2).

    Abstract translation: 用于防止或减少诸如无线电波的辐射信号的发射的诸如视觉显示单元（2）的电子设备（2）的屏蔽（1）包括：支撑视觉显示单元（2）的基座（8）和 在所述单元（2）上延伸并且与所述基座（8）牢固地电接合的盖（9）。 底座（8）为金属板，盖（9）由缝合在一起的单层镀镍编织聚酯纺织材料形成。 盖（9）和基座（8）通过金属化的钩和环紧固件（36,37）固定。 透明导电屏（44）提供对视觉显示单元（2）的视觉访问。

    Use of particular compounds for manufacture of pharmaceutical formulations for treatment against various parasites, mycoplasmas, other indications and other infections
    7.
    发明公开
    Use of particular compounds for manufacture of pharmaceutical formulations for treatment against various parasites, mycoplasmas, other indications and other infections 失效
    特殊化合物用于制造药物制剂以治疗各种寄生虫，MYCOPLASMAS，其他适应症和其他感染的用途

    公开(公告)号：EP0462621A3

    公开(公告)日：1993-03-17

    申请号：EP91110263.0

    申请日：1991-06-21

    Applicant: Prendergast, Patrick Thomas

    Inventor： Prendergast, Patrick Thomas

    IPC: A61K31/70

    CPC classification number: A61K31/70 ,  Y02A50/409 ,  Y02A50/492

    Abstract: One or more compounds are used for the manufacture of a pharmaceutical formulation for treatment against one or more kinds of parasites and/or one or more diseases caused by such parasites, against one or more kind of Mycoplasma and/or one or more diseases caused by such Mycoplasmas and/or against one or more of the following indications or infections (a) hairy leukoplakia, (b) oral candidosis, (c) mouth ulcerations-aphthous/herpetic/bacterial, (d) fungal candida, (e) human papilloma virus, (f) molluscum contagiosum, (g) squamous oral carcinoma, (h) Kaposi's sarcoma oral lesions, (i) periodontitis, 0) necrotizing gingivitis, (k) orofacial herpes zoster, and (I) rotaviruses. The present invention furthermore provides specific formulations including such compound(s).

Patent Agency Ranking